<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39339830</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Long-Term SARS-CoV-2 Findings Related to Persisting Viral Antigen and Inflammation Resemble Those Reported for Influenza Virus and Respiratory Syncytial Virus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1353</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091353</ELocationID><Abstract><AbstractText>Recent studies have documented prolonged expression of viral antigens and RNA and associated inflammation after infection with SARS-CoV-2 in a substantial proportion of infected patients. The persisting SARS-CoV-2 effects and findings, with inflammation associated with continued detection of viral antigens, especially resemble those previously reported for influenza virus, as well as respiratory syncytial virus (RSV). The reports indicate the need for improved insight into the mechanisms whereby post-SARS-CoV-2 infection-related illness is apparently more common and perhaps even more persistent after infection than observed for other respiratory viruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Norbert J</ForeName><Initials>NJ</Initials><Suffix>Jr</Suffix><Identifier Source="ORCID">0000-0002-4427-2986</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases and Immunology, Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="Y">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018357" MajorTopicYN="Y">Respiratory Syncytial Virus Infections</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018113" MajorTopicYN="N">Respiratory Syncytial Virus, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">asthenia</Keyword><Keyword MajorTopicYN="N">influenza virus</Keyword><Keyword MajorTopicYN="N">persisting inflammation</Keyword><Keyword MajorTopicYN="N">respiratory syncytial virus</Keyword><Keyword MajorTopicYN="N">viral RNA</Keyword><Keyword MajorTopicYN="N">viral antigen</Keyword></KeywordList><CoiStatement>The author declares no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339830</ArticleId><ArticleId IdType="pmc">PMC11436236</ArticleId><ArticleId IdType="doi">10.3390/v16091353</ArticleId><ArticleId IdType="pii">v16091353</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Choutka J., Jansari V., Hornig M., Iwasaki A. Unexplained post-acute infection syndromes. Nat. Med. 2022;28:911–923. doi: 10.1038/s41591-022-01810-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Machkovech H.M., Hahn A.M., Garonzik Wang J., Grubaugh N.D., Halfmann P.J., Johnson M.C., Lemieux J.E., O’Connor D.H., Piantadosi A., Wei W., et al. Persistent SARS-CoV-2 infection: Significance and implications. Lancet Infect. Dis. 2024;24:e453–e462. doi: 10.1016/S1473-3099(23)00815-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00815-0</ArticleId><ArticleId IdType="pubmed">38340735</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: A cohort study. Lancet Infect. Dis. 2024;24:239–255. doi: 10.1016/S1473-3099(23)00684-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00684-9</ArticleId><ArticleId IdType="pubmed">38104583</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Ryder D., Flavell R.R., Wang Y., Levi J., LaFranchi B.H., Deveau T.M., Buck A.M., Munter S.E., Asare K.A., et al. Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection. Sci. Transl. Med. 2024;16:eadk3295. doi: 10.1126/scitranslmed.adk3295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adk3295</ArticleId><ArticleId IdType="pmc">PMC11337933</ArticleId><ArticleId IdType="pubmed">38959327</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K., Peluso M.J., Luo X., Thomas R., Shin M.G., Neidleman J., Andrew A., Young K.C., Ma T., Hoh R., et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat. Immunol. 2024;25:218–225. doi: 10.1038/s41590-023-01724-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01724-6</ArticleId><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupi L., Vitiello A., Parolin C., Calistri A., Garzino-Demo A. The Potential Role of Viral Persistence in the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Pathogens. 2024;13:388. doi: 10.3390/pathogens13050388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens13050388</ArticleId><ArticleId IdType="pmc">PMC11123686</ArticleId><ArticleId IdType="pubmed">38787240</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif Z.A., Gomez C.R., Connors T.J., Henrich T.J., Reeves W.B., Force R.M.P.T. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC) Elife. 2023;12:e86002. doi: 10.7554/eLife.86002.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86002</ArticleId><ArticleId IdType="pmc">PMC10032659</ArticleId><ArticleId IdType="pubmed">36947108</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlateva K.T., de Vries J.J., Coenjaerts F.E., van Loon A.M., Verheij T., Little P., Butler C.C., Goossens H., Ieven M., Claas E.C., et al. Prolonged shedding of rhinovirus and re-infection in adults with respiratory tract illness. Eur. Respir. J. 2014;44:169–177. doi: 10.1183/09031936.00172113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00172113</ArticleId><ArticleId IdType="pubmed">24876172</ArticleId></ArticleIdList></Reference><Reference><Citation>Byington C.L., Ampofo K., Stockmann C., Adler F.R., Herbener A., Miller T., Sheng X., Blaschke A.J., Crisp R., Pavia A.T. Community Surveillance of Respiratory Viruses among Families in the Utah Better Identification of Germs-Longitudinal Viral Epidemiology (BIG-LoVE) Study. Clin. Infect. Dis. 2015;61:1217–1224. doi: 10.1093/cid/civ486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ486</ArticleId><ArticleId IdType="pmc">PMC4583580</ArticleId><ArticleId IdType="pubmed">26245665</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershenson M.B., Johnston S.L. Rhinovirus infections: More than a common cold. Am. J. Respir. Crit. Care Med. 2006;174:1284–1285. doi: 10.1164/rccm.200609-1387ED.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200609-1387ED</ArticleId><ArticleId IdType="pubmed">17158286</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowie D.M., Beaven P.W. On the clinical evidence of involvement of the suprarenal glands in influenza and influenzal pneumonia. Arch. Intern. Med. 1919;24:11. doi: 10.1001/archinte.1919.00090240081006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.1919.00090240081006</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luna X., Hartshorn K.L. Influenza Casts a Lung Shadow. Am. J. Pathol. 2017;187:697–699. doi: 10.1016/j.ajpath.2017.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2017.01.007</ArticleId><ArticleId IdType="pmc">PMC5397675</ArticleId><ArticleId IdType="pubmed">28222276</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakab G.J., Astry C.L., Warr G.A. Alveolitis induced by influenza virus. Am. Rev. Respir. Dis. 1983;128:730–739.</Citation><ArticleIdList><ArticleId IdType="pubmed">6625351</ArticleId></ArticleIdList></Reference><Reference><Citation>Pociask D.A., Robinson K.M., Chen K., McHugh K.J., Clay M.E., Huang G.T., Benos P.V., Janssen-Heininger Y.M.W., Kolls J.K., Anathy V., et al. Epigenetic and Transcriptomic Regulation of Lung Repair during Recovery from Influenza Infection. Am. J. Pathol. 2017;187:851–863. doi: 10.1016/j.ajpath.2016.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2016.12.012</ArticleId><ArticleId IdType="pmc">PMC5397680</ArticleId><ArticleId IdType="pubmed">28193481</ArticleId></ArticleIdList></Reference><Reference><Citation>Zammit D.J., Turner D.L., Klonowski K.D., Lefrancois L., Cauley L.S. Residual antigen presentation after influenza virus infection affects CD8 T cell activation and migration. Immunity. 2006;24:439–449. doi: 10.1016/j.immuni.2006.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.01.015</ArticleId><ArticleId IdType="pmc">PMC2861289</ArticleId><ArticleId IdType="pubmed">16618602</ArticleId></ArticleIdList></Reference><Reference><Citation>Keeler S.P., Agapov E.V., Hinojosa M.E., Letvin A.N., Wu K., Holtzman M.J. Influenza A Virus Infection Causes Chronic Lung Disease Linked to Sites of Active Viral RNA Remnants. J. Immunol. 2018;201:2354–2368. doi: 10.4049/jimmunol.1800671.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800671</ArticleId><ArticleId IdType="pmc">PMC6179922</ArticleId><ArticleId IdType="pubmed">30209189</ArticleId></ArticleIdList></Reference><Reference><Citation>Huckestein B.R., Zeng K., Westcott R., Alder J.K., Antos D., Kolls J.K., Alcorn J.F. Mammalian Target of Rapamycin Complex 1 Activation in Macrophages Contributes to Persistent Lung Inflammation following Respiratory Tract Viral Infection. Am. J. Pathol. 2024;194:384–401. doi: 10.1016/j.ajpath.2023.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2023.11.017</ArticleId><ArticleId IdType="pmc">PMC10913760</ArticleId><ArticleId IdType="pubmed">38159723</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong S.S., Oshansky C.M., Guo X.J., Ralston J., Wood T., Seeds R., Newbern C., Waite B., Reynolds G., Widdowson M.A., et al. Severe Influenza Is Characterized by Prolonged Immune Activation: Results from the SHIVERS Cohort Study. J. Infect. Dis. 2018;217:245–256. doi: 10.1093/infdis/jix571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix571</ArticleId><ArticleId IdType="pmc">PMC7335675</ArticleId><ArticleId IdType="pubmed">29112724</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermejo-Martin J.F., Garcia-Arevalo M.C., Alonso A., Lejarazu R.D., Pino M., Resino S., Tenorio A., Bernardo D., Leon A.J., Garrote J.A., et al. Persistence of proinflammatory response after severe respiratory syncytial virus disease in children. J. Allergy Clin. Immunol. 2007;119:1547–1550. doi: 10.1016/j.jaci.2007.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2007.03.014</ArticleId><ArticleId IdType="pubmed">17451801</ArticleId></ArticleIdList></Reference><Reference><Citation>Estripeaut D., Torres J.P., Somers C.S., Tagliabue C., Khokhar S., Bhoj V.G., Grube S.M., Wozniakowski A., Gomez A.M., Ramilo O., et al. Respiratory syncytial virus persistence in the lungs correlates with airway hyperreactivity in the mouse model. J. Infect. Dis. 2008;198:1435–1443. doi: 10.1086/592714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/592714</ArticleId><ArticleId IdType="pmc">PMC3689551</ArticleId><ArticleId IdType="pubmed">18828742</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarze J., O’Donnell D.R., Rohwedder A., Openshaw P.J. Latency and persistence of respiratory syncytial virus despite T cell immunity. Am. J. Respir. Crit. Care Med. 2004;169:801–805. doi: 10.1164/rccm.200308-1203OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200308-1203OC</ArticleId><ArticleId IdType="pubmed">14742302</ArticleId></ArticleIdList></Reference><Reference><Citation>Salamanna F., Veronesi F., Martini L., Landini M.P., Fini M. Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data. Front. Med. 2021;8:653516. doi: 10.3389/fmed.2021.653516.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.653516</ArticleId><ArticleId IdType="pmc">PMC8129035</ArticleId><ArticleId IdType="pubmed">34017846</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Z., Ahrnsbrak R., Rekito A. Evidence Mounts That About 7% of US Adults Have Had Long COVID. JAMA. 2024;332:5–6. doi: 10.1001/jama.2024.11370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2024.11370</ArticleId><ArticleId IdType="pubmed">38848092</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanth S.M., Huapaya J.A., Gairhe S., Wang H., Tian X., Demirkale C.Y., Hou C., Ma J., Kuhns D.B., Fink D.L., et al. Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19. Cell Rep. Med. 2024;5:101642. doi: 10.1016/j.xcrm.2024.101642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2024.101642</ArticleId><ArticleId IdType="pmc">PMC11293333</ArticleId><ArticleId IdType="pubmed">38981485</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng L.N., Bonilla H., Hedlin H., Jacobson K.B., Tian L., Jagannathan P., Yang P.C., Subramanian A.K., Liang J.W., Shen S., et al. Nirmatrelvir-Ritonavir and Symptoms in Adults with Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial. JAMA Intern. Med. 2024:E1–E11. doi: 10.1001/jamainternmed.2024.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2024.2007</ArticleId><ArticleId IdType="pmc">PMC11161857</ArticleId><ArticleId IdType="pubmed">38848477</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B., Ramasamy M.N. Synbiotics in post-acute COVID-19 syndrome-a potential new treatment framework? Lancet Infect. Dis. 2024;24:219–221. doi: 10.1016/S1473-3099(23)00735-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00735-1</ArticleId><ArticleId IdType="pubmed">38071991</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehar S., Boushra M., Ntiamoah P., Biehl M. Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’. Clevel. Clin. J. Med. 2021;91 doi: 10.3949/ccjm.88a.21010-up.</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.88a.21010-up</ArticleId><ArticleId IdType="pubmed">34625436</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandan J.S., Brown K., Simms-Williams N., Camaradou J., Bashir N., Heining D., Aiyegbusi O.L., Turner G., Cruz Rivera S., Hotham R., et al. Non-pharmacological therapies for postviral syndromes, including Long COVID: A systematic review and meta-analysis protocol. BMJ Open. 2022;12:e057885. doi: 10.1136/bmjopen-2021-057885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-057885</ArticleId><ArticleId IdType="pmc">PMC9002258</ArticleId><ArticleId IdType="pubmed">35410933</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D., Savale L., Noel N., Meyrignac O., Colle R., Gasnier M., Corruble E., Beurnier A., Jutant E.M., Pham T., et al. Post-acute COVID-19 syndrome. Eur. Respir. Rev. 2022;31 doi: 10.1183/16000617.0185-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0185-2021</ArticleId><ArticleId IdType="pmc">PMC8924706</ArticleId><ArticleId IdType="pubmed">35264409</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>